Overall, buff percentage is a critical factor that manufacturers of titanium dioxide must carefully manage to ensure the quality, consistency, and cost-effectiveness of their products. By investing in advanced technology and processes to control buff percentage, manufacturers can meet the specific requirements of their customers and maintain a competitive edge in the market. As the demand for titanium dioxide continues to grow across various industries, manufacturers must continue to innovate and improve their processes to meet the evolving needs of their customers.

In a 2017 study published in Scientific Reports, researchers exposed rats to human-relevant levels of E171 to examine the effects of intestinal inflammation and carcinogenesis. They saw that “a 100-day E171 treatment promoted colon microinflammation and initiated preneoplastic lesions while also fostering the growth of aberrant crypt foci in a chemically induced carcinogenesis model.” They continued: “Stimulation of immune cells isolated from Peyer’s Patches [which are clusters of lymphoid follicles found in the intestine] showed a decrease in Thelper (Th)-1 IFN-γ secretion, while splenic Th1/Th17 inflammatory responses sharply increased,” researchers wrote. “A 100-day titanium dioxide treatment promoted colon microinflammation and initiated preneoplastic lesions.” The scientists concluded: “These data should be considered for risk assessments of the susceptibility to Th17-driven autoimmune diseases and to colorectal cancer in humans exposed to TiO2 from dietary sources.”